Recently, JD Health announced that its independently developed medical large model, "Jingyi Qianxun," will be upgraded to version 2.0. This upgrade is not only a technological innovation but also a profound transformation of medical services, aiming to enhance the efficiency and accuracy of clinical diagnosis and treatment.
The 2.0 version of Jingyi Qianxun integrates multimodal perception and deep retrieval technologies, capable of consolidating clinical information from various sources. By combining real-world medical scenarios with data, this system provides doctors with a decision support tool that is more aligned with practical situations. The upgraded model demonstrates significant advantages in specialized disease treatment, particularly in handling complex malignant tumors and cardiovascular diseases, enabling better support for doctors in developing personalized treatment plans.
Image source note: Image generated by AI, licensed through Midjourney.
In specific terms, the new version of Jingyi Qianxun uses evidence-based medicine combined with individual patient data to provide clinical doctors with more precise diagnostic and treatment recommendations. Additionally, the introduction of an imaging pathology diagnosis module allows the system to quickly analyze medical images and pathological images, greatly reducing the workload of doctors while aiding clinical decision-making. This innovation enhances the efficiency of medical services while providing patients with safer and more reliable treatment experiences.
It is worth noting that during the upgrade process, Jingyi Qianxun actively incorporated user feedback and continuously optimized model performance to ensure its effectiveness and usability in real-world applications. The release of version 2.0 marks an important milestone for JD Health in the field of medical artificial intelligence, signaling further advancement in intelligent healthcare.
Meanwhile, there have been some changes in management at JD Health. Li Xin, the general manager of the technical product department responsible for the Jingyi Qianxun project, has left, and future operations will be directly managed by JD Health's CEO Jin Enlin, which will provide higher-level support for the model's continued development.
Through technological innovation and management optimization, Jingyi Qianxun 2.0 will bring more possibilities to the healthcare industry, assisting both doctors and patients in embracing the new era of intelligent healthcare.